HelixBind_Logo_AS2-no BG (2018).png
FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
August 24, 2020 11:47 ET | HelixBind
BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Professor Gordon Dougan Receives the 2020 Albert B. Sabin Gold Medal
August 13, 2020 10:00 ET | The Sabin Vaccine Institute
Washington, D.C., Aug. 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that it has awarded its annual Albert B. Sabin Gold Medal to Gordon Dougan, FRS, professor in...
HelixBind_Logo_AS2-no BG (2018).png
HelixBind Awarded $3MM Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease
July 16, 2020 12:01 ET | HelixBind
BOXBOROUGH, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for patients afflicted with invasive microbial infections,...
HelixBind_Logo_AS2-no BG (2018).png
HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections
June 10, 2020 10:29 ET | HelixBind
BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Phase Genomics Receives $1.5MM NIH Grant to Develop Fast and Affordable Commercial Antimicrobial Resistance Tracking Kit
January 08, 2020 09:30 ET | Phase Genomics
SEATTLE, Washington, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity-ligation next-generation sequencing (NGS) solutions for metagenome assembly, today...
_Logo_May 2014_low res.png
Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
September 03, 2019 07:00 ET | Allecra Therapeutics GmbH
LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
August 07, 2019 10:00 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
DNV GL Healthcare Focuses on Overcoming Antimicrobial Resistance in Nation's Hospitals
May 29, 2019 16:27 ET | DNV GL Business Assurance USA, Inc.
MILFORD, OHIO, May 29, 2019 (GLOBE NEWSWIRE) -- As the Centers for Disease Control and Prevention (CDC) ramps up the nation’s attempts to neutralize antibiotic/anti-microbial resistance (AMR) in...
NEWAspaLogoLrger.png
Louisiana Restaurants to Disclose Use of Foreign Shrimp and Crawfish
May 29, 2019 13:28 ET | American Shrimp Processors Association
BILOXI, Miss., May 29, 2019 (GLOBE NEWSWIRE) -- In a move to protect Louisiana consumers from “the health risks associated chemicals and residues in imported seafood,” the Louisiana Senate...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
March 18, 2019 11:00 ET | BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...